ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
leverage factor · long-only model fund

Foundry Healthcare OPLev Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FOPHHYPOTHETICAL MODEL
Since ’99
−51%
Expense Ratio
0.45%
placeholder
Holdings
96
cap-weighted
Inception
Nov 2019
placeholder
Full Sharpe
0.05
Ann. Return (LS)
1.5%
Ann. Volatility
28.1%
Max Drawdown
-76.1%
Test Sharpe ’19–26
-0.19
Test FF5 α (ann.)
-14.4%
vs Fama-French 5
Test FF5 α t-stat
-1.70
not significant
Monthly turnover
7%
of the long leg, per rebalance
Cumulative return (LS)
-51%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.72
what this fund holds
Long leg ann. return
13.1%
buyable, long-only
Long-short Sharpe
0.05
requires shorting
Bottom bucket ann. return
11.7%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

96 of 96 · 100.0% of book
TickerCompanySectorMarket capWeight
1UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
30.52%
2CVS
CVS HEALTH CORPHealthcare$137.12B
10.81%
3MCK
MCKESSON CORPHealthcare$101.14B
7.98%
4ELV
ELEVANCE HEALTH INCHealthcare$80.92B
6.38%
5CI
CIGNA GROUPHealthcare$74.45B
5.87%
6COR
CENCORA INCHealthcare$59.91B
4.72%
7CAH
CARDINAL HEALTH INCHealthcare$53.52B
4.22%
8HUM
HUMANA INCHealthcare$48.02B
3.79%
9IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
3.53%
10NTRA
NATERA INCHealthcare$38.87B
3.07%
11CNC
CENTENE CORPHealthcare$32.81B
2.59%
12MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
1.21%
13BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
1.08%
14MDGL
MADRIGAL PHARMACEUTICALS INCHealthcare$12.76B
1.01%
15AXSM
AXSOME THERAPEUTICS INCHealthcare$11.84B
0.93%
16MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
0.93%
17SMMT
SUMMIT THERAPEUTICS INCHealthcare$10.72B
0.85%
18ENSG
ENSIGN GROUP INCHealthcare$10.01B
0.79%
19HSIC
HENRY SCHEIN INCHealthcare$10.00B
0.79%
20UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.72%
21OSCR
OSCAR HEALTH INCHealthcare$8.77B
0.69%
22PACS
PACS GROUP INCHealthcare$7.30B
0.58%
23CHE
CHEMED CORPHealthcare$6.77B
0.53%
24HNGE
HINGE HEALTH INCHealthcare$6.74B
0.53%
25ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
0.34%
26OPCH
OPTION CARE HEALTH INCHealthcare$3.41B
0.27%
27PRVA
PRIVIA HEALTH GROUP INCHealthcare$3.39B
0.27%
28WRBY
WARBY PARKER INCHealthcare$3.24B
0.26%
29TARS
TARSUS PHARMACEUTICALS INCHealthcare$2.58B
0.20%
30GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.20%
31ASTH
ASTRANA HEALTH INCHealthcare$2.50B
0.20%
32PGNY
PROGYNY INCHealthcare$2.50B
0.20%
33BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.19%
34AGL
AGILON HEALTH INCHealthcare$2.17B
0.17%
35MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.17%
36ADUS
ADDUS HOMECARE CORPHealthcare$2.14B
0.17%
37AVAH
AVEANNA HEALTHCARE HOLDINGS INCHealthcare$2.11B
0.17%
38CDNA
CAREDX INCHealthcare$2.05B
0.16%
39WGS
GENEDX HOLDINGS CORPHealthcare$1.88B
0.15%
40NVCR
NOVOCURE LTDHealthcare$1.84B
0.15%
41HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.14%
42FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.13%
43INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.12%
44PNTG
PENNANT GROUP INCHealthcare$1.46B
0.12%
45INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.11%
46ARDT
ARDENT HEALTH INCHealthcare$1.46B
0.11%
47OMDA
OMADA HEALTH INCHealthcare$1.41B
0.11%
48AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.11%
49PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.11%
50ATEC
ALPHATEC HOLDINGS INCHealthcare$1.31B
0.10%
51ARDX
ARDELYX INCHealthcare$1.28B
0.10%
52TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.09%
53ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.09%
54TALK
TALKSPACE INCHealthcare$873M
0.07%
55PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.07%
56SIBN
SI-BONE INCHealthcare$771M
0.06%
57CBLL
CERIBELL INCHealthcare$710M
0.06%
58SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.05%
59EVH
EVOLENT HEALTH INCHealthcare$654M
0.05%
60TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.05%
61ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.05%
62MYGN
MYRIAD GENETICS INCHealthcare$584M
0.05%
63WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.05%
64ANGO
ANGIODYNAMICS INCHealthcare$558M
0.04%
65NPCE
NEUROPACE INCHealthcare$548M
0.04%
66TOI
ONCOLOGY INSTITUTE INCHealthcare$535M
0.04%
67NRC
NRC HEALTHHealthcare$491M
0.04%
68OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
0.04%
69VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.04%
70CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.03%
71EOLS
EVOLUS INCHealthcare$377M
0.03%
72FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.03%
73ELMD
ELECTROMED INCHealthcare$349M
0.03%
74CV
CAPSOVISION INCHealthcare$335M
0.03%
75SGHT
SIGHT SCIENCES INCHealthcare$274M
0.02%
76SMTI
SANARA MEDTECH INCHealthcare$229M
0.02%
77KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.02%
78SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.02%
79BDSX
BIODESIX INCHealthcare$204M
0.02%
80FOCL
FOCAL INCHealthcare$204M
0.02%
81PDEX
PRO DEX INCHealthcare$183M
0.01%
82INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.01%
83INGN
INOGEN INCHealthcare$178M
0.01%
84OWLT
OWLET INCHealthcare$162M
0.01%
85RCEL
AVITA MEDICAL INCHealthcare$157M
0.01%
86JYNT
JOINT CORPHealthcare$127M
0.01%
87VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.01%
88CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.01%
89NRXS
NEURAXIS INCHealthcare$84M
0.01%
90FRMM
FORUM MARKETS INCHealthcare$83M
0.01%
91PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.01%
92ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.01%
93SCLX
SCILEX HOLDING COHealthcare$72M
0.01%
94LNSR
LENSAR INCHealthcare$70M
0.01%
95SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.00%
96EXOZ
EXOZYMES INCHealthcare$51M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $1.27T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

96 classified
Value
Blend
Growth
Large
Mid
Small
18%5
54%10
23%10
1%6
1%6
2%11
<1%6
<1%12
<1%14

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 53% toward Growth. +1% unclassified (16 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt97% → Large
SmallLarge
Value ↔ growth tilt53% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 96 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    63.4%
    Margin
    -11.6%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    30.5%
    Margin
    -5.5%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 96 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.4 (95% CI 0.9-1.5)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
13.9%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.45x
within
parametric
1.13x
within
cornish fisher
1.12x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 28%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2011
Before publication (pre-2011)
0.00
Sharpe · 0.0% p.a.
January 1999December 2011 · 156 mo
Since publication
0.12
Sharpe · 2.7% p.a.
January 2012July 2026 · 175 mo
Change in Sharpe+0.12Sharpe strengthened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
58%
15 of 26 3-year windows made money
Worst window
-0.80
Sharpe, January 2011 – December 2013
January 1999July 2026
Median Sharpe
0.32
Dispersion
0.59
Best window
1.41

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.41.6%-30.5%
3 yearsp.a.2.6%-21.4%
5 yearsp.a.3.5%-3.3%
10 yearsp.a.10.6%-1.5%
Since inceptionp.a.12.1%-2.6%
Calendar years
YearLong legLong-short
20267 mo14.0%-15.2%
2025-0.5%-34.8%
2024-7.8%-8.2%
20231.7%-7.4%
20220.6%47.9%
202131.6%14.4%
202019.8%-26.1%
201922.0%-12.7%
20188.8%36.7%
201724.5%12.4%
20161.5%39.0%
20159.1%9.4%
201430.4%8.3%
201346.3%-7.1%
201212.5%-16.2%
201115.1%-5.8%
201016.3%9.7%
200930.5%10.4%
2008-42.1%-42.8%
200714.2%27.7%
2006-0.1%5.8%
200529.5%11.8%
200424.9%17.0%
200335.1%-20.1%
20020.7%76.7%
2001-9.1%-1.8%
200098.8%-18.9%
1999-23.8%-62.9%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FOPH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-11-04 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$1.27T

Methodology

The Foundry Healthcare OPLev Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a OPLev signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.